

Altus Pharmaceuticals Inc.  
Form 8-K  
July 25, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): July 24, 2006  
ALTUS PHARMACEUTICALS INC.  
(Exact name of registrant as specified in its charter)**

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-51711**  
(Commission  
File Number)

**04-3573277**  
(I.R.S. Employer  
Identification No.)

**125 Sidney Street, Cambridge, Massachusetts**  
(Address of principal executive offices)

**02139**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 299-2900**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

**SIGNATURES**

EX-99.1 Press Release dated July 24, 2006

---

**Table of Contents**

**Item 8.01. Other Events.**

On July 24, 2006, Altus Pharmaceuticals Inc. (the Company ) issued a press release announcing an update on the Company s plans for initiation of Phase III clinical trials for ALTU-135, the Company s orally administered enzyme replacement therapy and ALTU-238, the Company s long-acting, crystalline form of human growth hormone. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

The Company held a conference call and simultaneous webcast to discuss these updates on July 24, 2006. A replay of the webcast is available on [www.altus.com](http://www.altus.com) through August 24, 2006 and through 11:59 p.m. eastern time July 31, 2006 by dialing 888-203-1112 or 719-457-0820. The replay passcode is 4102909.

**Item 9.01. Financial Statements and Exhibits.**

(d) The following exhibits are furnished with this report:

| <u>Exhibit Number</u> | <u>Description</u>                |
|-----------------------|-----------------------------------|
| 99.1                  | Press Release dated July 24, 2006 |

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALTUS PHARMACEUTICALS INC.**

By: /s/ Jonathan I. Lieber  
Jonathan I. Lieber  
Vice President, Chief Financial Officer  
and Treasurer

Date: July 25, 2006

3